- Home
- OPCH vs RLAY Comparison
OPCH vs RLAY Comparison
Compare OPCH & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OPCH | RLAY |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 3.8B |
| IPO Year | 1996 | 2020 |
Fundamental Metrics
Financial Performance| Metric | OPCH | RLAY |
|---|---|---|
| Price | $31.66 | $19.87 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 12 |
| Target Price | ★ $30.03 | $28.25 |
| AVG Volume (30 Days) | ★ 3.2M | 2.5M |
| Earning Date | 11-04-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 3.25 | ★ 31.78 |
| EPS | ★ 1.02 | N/A |
| Revenue | ★ $4,998,202,000.00 | $15,355,000.00 |
| Revenue This Year | $1.91 | N/A |
| Revenue Next Year | $6.41 | $63.45 |
| P/E Ratio | $31.02 | ★ N/A |
| Revenue Growth | 16.17 | ★ 53.44 |
| 52 Week Low | $18.01 | $6.04 |
| 52 Week High | $36.80 | $21.27 |
Technical Indicators
Market Signals| Indicator | OPCH | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 75.70 | 57.67 |
| Support Level | $28.70 | $17.45 |
| Resistance Level | $31.90 | $20.31 |
| Average True Range (ATR) | 0.16 | 1.19 |
| MACD | -0.26 | 0.22 |
| Stochastic Oscillator | 61.76 | 74.55 |
Price Performance
Historical ComparisonAbout OPCH Option Care Health Inc.
Option Care Health Inc is the provider of home and alternate-site infusion services. It provides treatment for bleeding disorders, neurological disorders, heart failure, anti-infectives, and chronic inflammatory disorders, among others. The Company operates in one segment, infusion services.
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.